title: Soy β-conglycinin retards progression of diabetic nephropathy via modulating the insulin sensitivity and angiotensin-converting enzyme activity in rats fed with high salt diet.
abstract: Soy protein was known to have renal-protective effects. The aim of this study was to investigate the effects of different doses of soybean β-conglycinin, one of the main storage proteins in soy, on diabetic nephropathy in the rat. We used 40 Wistar rats with eight rats in each group. Diabetes mellitus was induced in rats by an intravenous injection of streptozotocin. The groups included a control group (Ctrl) fed with the standard AIN93-M diet, while other groups were fed with AIN-93M with the addition of NaCl to induce diabetic nephropathy (DN). DN rats were divided into the DN control (DN) group, the soy protein (DN + SP) group, the low-dose β-conglycinin (DN + B) group, and the high-dose β-conglycinin (DN + 2B) group. After a 27 weeks experimental period, we found that soy protein and β-conglycinin decreased blood glucose via increasing the insulin sensitivity, with an enhanced cholesterol-lowering effect of β-conglycinin-mediated hepatic LDL receptor protein expression. Otherwise, there were beneficial effects of soy protein and β-conglycinin on renal function markers. Through the inhibition of angiotensin-converting enzyme (ACE), soy protein and β-conglycinin retarded the progression of diabetic nephropathy by decreasing the blood pressure and histological changes. In conclusion, soy protein and β-conglycinin may retard the progression of diabetic nephropathy by increasing insulin sensitivity, regulating lipid metabolism, improving renal function markers, and inhibiting ACE activity.
authors.affiliation: School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan. syunei@tmu.edu.tw.
authors.forename: Wan-Ju
authors.initials: WJ
authors.lastname: Yeh
authors.forename: Hsin-Yi
authors.initials: HY
authors.lastname: Yang
authors.forename: Jiun-Rong
authors.initials: JR
authors.lastname: Chen
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D052179:Antigens, Plant / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D003401:Creatine / Q000097:blood / Q000652:urine; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005916:Globulins / Q000494:pharmacology*; D007333:Insulin Resistance; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D047495:PPAR gamma / Q000378:metabolism; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D018110:Receptors, Lipoprotein / Q000378:metabolism; D055314:Seed Storage Proteins / Q000494:pharmacology*; D012709:Serum Albumin / Q000378:metabolism; D017673:Sodium Chloride, Dietary / Q000008:administration & dosage* / Q000009:adverse effects; D030262:Soybean Proteins / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015854:Up-Regulation
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D052179:Antigens, Plant; D001786:Blood Glucose; D005916:Globulins; D047495:PPAR gamma; D018110:Receptors, Lipoprotein; D055314:Seed Storage Proteins; D012709:Serum Albumin; D017673:Sodium Chloride, Dietary; D030262:Soybean Proteins; D014409:Tumor Necrosis Factor-alpha; C013894:beta-conglycinin protein, Glycine max; D007703:Peptidyl-Dipeptidase A; D003401:Creatine